AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01617707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol
Description: In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
Study NCT04282265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
Study NCT04282265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Spinach Extract (RSE)
Description: Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
Study NCT01421303 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: Enbrel
Study NCT00813605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion
Study NCT00813605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion
Study NCT00813605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
Study NCT00813605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive dummy agent (to maintain blind)
Study NCT00813605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inactive dummy agent (to maintain blind)
Study NCT00813605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
Study NCT03822598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques, TRT
Description: TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
Study NCT03822598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching Recovery Techniques, TRT
Description: TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
Study NCT04518150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri balloon
Description: the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study NCT04518150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri balloon
Description: the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study NCT01617707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
Study NCT01959607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own cigarette (CC)
Study NCT01959607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT Gum
Description: Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
Study NCT03510598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting machine will be used to perform the treatments.
Study NCT03510598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kybella 20 MG in 2 ML Injection
Description: Injectable drug called KYBELLA® (deoxycholic acid)
Study NCT00464438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gatifloxacin
Description: Day 1-6 = 1 drop of study medication three times a day
Study NCT00464438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin
Description: Day 1-6 = 1 drop of study medication three times a day
Study NCT00464438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0.5% eye drops
Description: Day 1-6 = 1 drop of study medication three times a day
Study NCT04735926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 75mcg
Description: Soft gelatin capsule. Oral administration once per week
Study NCT04735926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 100mcg
Description: Soft gelatin capsule. Oral administration once per week
Study NCT04735926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 125mcg
Description: Soft gelatin capsule. Oral administration once per week.
Study NCT04735926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.
Study NCT04735926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.
Study NCT04665466 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.
Study NCT04518150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Uterine Artery Ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
Study NCT03066089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfuro
Study NCT04286841 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
Study NCT00987428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonography with or not sphincterotomy
Description: Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
Study NCT00987428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual procedure
Description: The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
Study NCT04960904 — intervention group
Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.
Study NCT02901002 — intervention group
Intervention type: OTHER
Intervention: Sensory testing in the two hand
Description: spontaneous sensations while watching a hand
Study NCT02901002 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Score to anxiety-depression scale
Study NCT00338208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the Use of Low Vision Devices
Study NCT03195244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Physical Therapy
Description: Swim Whisperer's Aquatic Therapy Sessions
Study NCT03195244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Physical Therapy
Description: Swim Whisperer's Aquatic Therapy Sessions
Study NCT01980303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
Study NCT00211393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 600mg. /day for 6 weeks
Study NCT04151927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation.
Study NCT04151927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric Hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation.
Study NCT04151927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Normoxia
Description: Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
Study NCT04151927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric Normoxia
Description: Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
Study NCT01456195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fasiglifam placebo-matching tablets
Study NCT01456195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets
Study NCT00134654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin
Description: Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
Study NCT02938832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on what food to choose and eat
Description: Dietary advice
Study NCT00791479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265 and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study NCT00398060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral life-style counseling
Study NCT01311570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.
Study NCT01954602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guide-wire cannulation
Description: Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
Study NCT01954602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphincterotome assisted guide-wire cannulation
Description: Sphincterotome is inserted initially a few millimeters through the papillary orifice
Study NCT04462549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Facilitation
Description: RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification.
Study NCT03977194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 every 4 weeks
Study NCT03977194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 every 4 weeks
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
Study NCT02448420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibody-Drug Conjugates
Description: 3.6 mg/kg iv every 3 weeks
Study NCT02959944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib capsules administered orally daily
Study NCT02959944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally daily
Study NCT02959944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone administered daily
Study NCT02959944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone administered daily
Study NCT02520843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction (SVF)
Description: stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
Study NCT02496897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-02.2 Vaccine
Description: Synthetic Peptide Hepatitis B Vaccine
Study NCT02496897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02496897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IC31® Adjuvant
Description: IC31® Adjuvant
Study NCT04519684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Allogeneic bone marrow derived mesenchymal stem cells
Study NCT04519684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT04350840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback
Description: feedback of optical diagnosis performance per 3 month
Study NCT03428789 — intervention group
Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
Study NCT01407640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allergy tests
Description: 1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
Study NCT03454893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVR-RD-01
Description: Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
Study NCT02071251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective wound complication protocol
Description: The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
Study NCT00791479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study NCT02867943 — intervention group
Intervention type: OTHER
Intervention: Effects of respiratory rate on gapCO2
Description: respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
Study NCT03098251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D typing
Description: typing the patient with 3D typing system and give specific treatment
Study NCT03098251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine typing
Description: typing the patient with routine typing system and give specific treatment
Study NCT01814098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
Study NCT02862483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg
Study NCT02862483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Study NCT02862483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Study NCT02862483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Tamsulosin
Study NCT04421729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions over 3 weeks
Description: Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
Study NCT04421729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions over 6 weeks
Description: Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
Study NCT02683889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
Study NCT00515294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeinated Alcoholic Beer
Description: Alcoholic Beer plus Caffeine Citrate powder.
Study NCT00515294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Caffeinated Alcoholic Beer
Description: Alcoholic Non-Caffeinated Beer
Study NCT03977194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m² D1, 8, 15, every 4 weeks
Study NCT00515294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeinated Non-Alcoholic Beer
Description: Non-Alcoholic Beer plus Caffeine Citrate powder.
Study NCT00515294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Caffeinated, Non-Alcoholic Beer
Description: Non-Alcoholic Beer
Study NCT03977194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m² D1, 8, 15, every 4 weeks
Study NCT03977194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks
Study NCT03678792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine/naloxone
Description: Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
Study NCT03678792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
Study NCT03678792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
Study NCT01953679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Study NCT02534285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hearing protection
Description: Attenuation of hearing during surgery
Study NCT02534285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing protection
Description: Attenuation of hearing during surgery